Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Liabilities and Shareholders Equity (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Liabilities and Shareholders Equity data on record, last reported at $494.7 million in Q3 2023.

  • For Q3 2023, Liabilities and Shareholders Equity fell 19.85% year-over-year to $494.7 million; the TTM value through Dec 2023 reached $1.5 billion, down 32.91%, while the annual FY2022 figure was $561.1 million, 28.35% up from the prior year.
  • Liabilities and Shareholders Equity reached $494.7 million in Q3 2023 per CGEM's latest filing, down from $522.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $667.2 million in Q2 2022 and bottomed at $214.7 million in Q4 2020.
  • Average Liabilities and Shareholders Equity over 4 years is $488.7 million, with a median of $487.2 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 103.62% in 2021, then fell 21.77% in 2023.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $214.7 million in 2020, then skyrocketed by 103.62% to $437.2 million in 2021, then rose by 28.35% to $561.1 million in 2022, then dropped by 11.84% to $494.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $494.7 million in Q3 2023, $522.0 million in Q2 2023, and $515.0 million in Q1 2023.